{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine whether dapagliflozin is superior to placebo, when added to standard of care, in reducing the incidence of CV death or a HF event (hospitalisation for HF or equivalent HF event, i.e., an urgent HF visit).",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective 1",
        "text": "To compare the effect of dapagliflozin versus placebo on CV death or hospitalisation for HF.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective 2",
        "text": "To compare the effect of dapagliflozin versus placebo on total number of recurrent HF hospitalisations and CV death.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective 3",
        "text": "To compare the effect of treatment with dapagliflozin versus placebo on the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score for HF symptoms and physical limitations.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective 4",
        "text": "To determine if dapagliflozin compared with placebo reduces the incidence of a composite endpoint of worsening renal function.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective 5",
        "text": "To determine whether dapagliflozin, compared with placebo, reduces the incidence of all-cause mortality.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Safety Objective",
        "text": "To evaluate the safety and tolerability of dapagliflozin in this patient population.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective 1",
        "text": "To compare the effect of dapagliflozin versus placebo on an expanded composite outcome reflecting worsening of HF.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 2",
        "text": "To determine whether dapagliflozin compared with placebo will have effect on New York Heart Association (NYHA) class.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 3",
        "text": "To determine whether dapagliflozin compared with placebo will reduce the incidence of diagnosis of atrial fibrillation (AF) in patients without history of AF at baseline.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 4",
        "text": "To determine whether dapagliflozin compared with placebo will result in a reduction of the incidence of hyper – and hypokalaemia.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 5",
        "text": "To determine whether dapagliflozin compared with placebo will affect the number of events of doubling of serum creatinine.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 6",
        "text": "To determine whether dapagliflozin compared with placebo will reduce the incidence of diagnosis of T2D in patients without diabetes at baseline.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_14",
        "name": "Exploratory Objective 7",
        "text": "To determine whether dapagliflozin compared with placebo will have effect on HbA1c in T2D subgroup.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_15",
        "name": "Exploratory Objective 8",
        "text": "To determine whether dapagliflozin compared with placebo will have an effect on systolic BP.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_18"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Outcome Measure",
        "text": "Time to the first occurrence of any of the components of this composite: 1. CV death 2. Hospitalisation for HF 3. An urgent HF visit",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Outcome Measure 1",
        "text": "Time to the first occurrence of either of the components of this composite: 1. CV death 2. Hospitalisation for HF",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Outcome Measure 2",
        "text": "Total number of (first and recurrent) HF hospitalisations and CV death.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Outcome Measure 3",
        "text": "Change from baseline measured at 8 months in the total symptom score of the KCCQ, a specific HF patient reported outcome questionnaire.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_5",
        "name": "Secondary Outcome Measure 4",
        "text": "Time to the first occurrence of any of the components of this composite: 1. ≥50% sustained* decline in eGFR 2. Reaching End Stage Renal Disease (ESRD) 3. Renal death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Outcome Measure 5",
        "text": "Time to death from any cause.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Safety Outcome Measure 1",
        "text": "Serious Adverse Events (SAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "Safety Outcome Measure 2",
        "text": "Discontinuation of IP due to Adverse Events (DAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_9",
        "name": "Safety Outcome Measure 3",
        "text": "Changes in clinical chemistry/haematology parameters",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Safety Outcome Measure 4",
        "text": "AEs of interest (volume depletion, renal events, major hypoglycaemic events, fractures, Diabetic ketoacidosis (DKA), AEs leading to amputation and AEs leading to a risk for lower limb amputations [“preceding events”])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Outcome Measure 1",
        "text": "Time to the first occurrence of any of the components of the expanded composite worsening HF outcome: 1. CV death 2. Hospitalisation for HF 3. An urgent HF visit 4. Documented evidence of worsening HF symptoms/signs leading to initiation of a new treatment for HF sustained for at least 4 weeks or augmentation of existing oral therapy for HF (eg, increase in dose of diuretic) sustained for at least 4 weeks.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Outcome Measure 2",
        "text": "Change in NYHA class from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Outcome Measure 3",
        "text": "Proportion of patients without history of AF at baseline with a new diagnosis of AF during the study.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Outcome Measure 4",
        "text": "Time to the first occurrence of each of any of the following central lab levels of serum potassium: >6.0 mmol/L, >5.5 mmol/L, <3.5 mmol/L, <3.0 mmol/L",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Outcome Measure 5",
        "text": "Number of events with doubling of serum creatinine (compared with the most recent laboratory measurement).",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Outcome Measure 6",
        "text": "Proportion of patients without T2D at baseline with a new diagnosis of T2D during the study.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Outcome Measure 7",
        "text": "Changes in HbA1c from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Outcome Measure 8",
        "text": "Change in systolic BP from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 6,
      "exploratoryObjectives": 8,
      "totalEndpoints": 18,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine whether dapagliflozin is superior to placebo, when added to standard of care, in reducing the incidence of CV death or a HF event (hospitalisation for HF or equivalent HF event, i.e., an urgent HF visit).",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective 1",
        "text": "To compare the effect of dapagliflozin versus placebo on CV death or hospitalisation for HF.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective 2",
        "text": "To compare the effect of dapagliflozin versus placebo on total number of recurrent HF hospitalisations and CV death.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective 3",
        "text": "To compare the effect of treatment with dapagliflozin versus placebo on the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score for HF symptoms and physical limitations.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective 4",
        "text": "To determine if dapagliflozin compared with placebo reduces the incidence of a composite endpoint of worsening renal function.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective 5",
        "text": "To determine whether dapagliflozin, compared with placebo, reduces the incidence of all-cause mortality.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Safety Objective",
        "text": "To evaluate the safety and tolerability of dapagliflozin in this patient population.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Exploratory Objective 1",
        "text": "To compare the effect of dapagliflozin versus placebo on an expanded composite outcome reflecting worsening of HF.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Exploratory Objective 2",
        "text": "To determine whether dapagliflozin compared with placebo will have effect on New York Heart Association (NYHA) class.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Exploratory Objective 3",
        "text": "To determine whether dapagliflozin compared with placebo will reduce the incidence of diagnosis of atrial fibrillation (AF) in patients without history of AF at baseline.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Exploratory Objective 4",
        "text": "To determine whether dapagliflozin compared with placebo will result in a reduction of the incidence of hyper – and hypokalaemia.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective 5",
        "text": "To determine whether dapagliflozin compared with placebo will affect the number of events of doubling of serum creatinine.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_13",
        "name": "Exploratory Objective 6",
        "text": "To determine whether dapagliflozin compared with placebo will reduce the incidence of diagnosis of T2D in patients without diabetes at baseline.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_14",
        "name": "Exploratory Objective 7",
        "text": "To determine whether dapagliflozin compared with placebo will have effect on HbA1c in T2D subgroup.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_15",
        "name": "Exploratory Objective 8",
        "text": "To determine whether dapagliflozin compared with placebo will have an effect on systolic BP.",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_18"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Outcome Measure",
        "text": "Time to the first occurrence of any of the components of this composite: 1. CV death 2. Hospitalisation for HF 3. An urgent HF visit",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Outcome Measure 1",
        "text": "Time to the first occurrence of either of the components of this composite: 1. CV death 2. Hospitalisation for HF",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Outcome Measure 2",
        "text": "Total number of (first and recurrent) HF hospitalisations and CV death.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Outcome Measure 3",
        "text": "Change from baseline measured at 8 months in the total symptom score of the KCCQ, a specific HF patient reported outcome questionnaire.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_5",
        "name": "Secondary Outcome Measure 4",
        "text": "Time to the first occurrence of any of the components of this composite: 1. ≥50% sustained* decline in eGFR 2. Reaching End Stage Renal Disease (ESRD) 3. Renal death",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Outcome Measure 5",
        "text": "Time to death from any cause.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Safety Outcome Measure 1",
        "text": "Serious Adverse Events (SAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "Safety Outcome Measure 2",
        "text": "Discontinuation of IP due to Adverse Events (DAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_9",
        "name": "Safety Outcome Measure 3",
        "text": "Changes in clinical chemistry/haematology parameters",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_10",
        "name": "Safety Outcome Measure 4",
        "text": "AEs of interest (volume depletion, renal events, major hypoglycaemic events, fractures, Diabetic ketoacidosis (DKA), AEs leading to amputation and AEs leading to a risk for lower limb amputations [“preceding events”])",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_11",
        "name": "Exploratory Outcome Measure 1",
        "text": "Time to the first occurrence of any of the components of the expanded composite worsening HF outcome: 1. CV death 2. Hospitalisation for HF 3. An urgent HF visit 4. Documented evidence of worsening HF symptoms/signs leading to initiation of a new treatment for HF sustained for at least 4 weeks or augmentation of existing oral therapy for HF (eg, increase in dose of diuretic) sustained for at least 4 weeks.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Exploratory Outcome Measure 2",
        "text": "Change in NYHA class from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_13",
        "name": "Exploratory Outcome Measure 3",
        "text": "Proportion of patients without history of AF at baseline with a new diagnosis of AF during the study.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_14",
        "name": "Exploratory Outcome Measure 4",
        "text": "Time to the first occurrence of each of any of the following central lab levels of serum potassium: >6.0 mmol/L, >5.5 mmol/L, <3.5 mmol/L, <3.0 mmol/L",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "Exploratory Outcome Measure 5",
        "text": "Number of events with doubling of serum creatinine (compared with the most recent laboratory measurement).",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_16",
        "name": "Exploratory Outcome Measure 6",
        "text": "Proportion of patients without T2D at baseline with a new diagnosis of T2D during the study.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_17",
        "name": "Exploratory Outcome Measure 7",
        "text": "Changes in HbA1c from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_18",
        "name": "Exploratory Outcome Measure 8",
        "text": "Change in systolic BP from baseline.",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      }
    ],
    "estimands": []
  }
}